Syngene International share price
NSE: SYNGENEBSE: 539268Healthcare ServicesSmall Cap
Syngene International Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2015
Last close ₹398.60down ₹12.25 (2.98%)BSE ₹398.30
Share price at the NSE close on 29 Oct 2026. Previous close ₹410.85.
29 Oct: open ₹413.00, high ₹414.70, low ₹396.00
52-week range of traded prices to 29 Oct 2026
₹344.45Low, 9 Oct 2026₹678.95High, 7 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,090 Cr359th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 86.46
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹97 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 56.88
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹97 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 5.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 35,12,68730.0% delivered
About Syngene International
Syngene International Limited is a Bengaluru-based contract research, development and manufacturing organisation (CRDMO) that takes drug molecules from early research through development to commercial-scale manufacturing for its clients.12 It serves large, mid-sized and emerging biopharma companies as well as nutrition, animal health, consumer goods and specialty chemical businesses, from campuses in Bengaluru, Hyderabad and Mangaluru.32
It works across small molecules (chemically made drugs), peptides, biologics (drugs made from living cells), antibody-drug conjugates and oligonucleotides (short synthetic strands of DNA or RNA).3 Its Research Services comprise Discovery Services, Dedicated Centers (research sites run for a single client) and Translational & Clinical Research (early-phase clinical trials), while its development and manufacturing business makes small and large molecules for clinical trials and commercial supply.456 Clients hire it through models that include dedicated labs, full-time-equivalent teams and fee-for-service work; Syngene performs research on behalf of its clients on a contract basis and assigns the intellectual property to them.789 Its named platforms include Syn.AI, SARchitect and SynVent.510 At the end of March 2026 it had 8,373 employees, including 5,778 scientists.11
Syngene was incorporated on 18 Nov 1993, began operations as a contract research organisation in 1994 and listed on the stock exchanges in 2015.1213 It bought its Unit 3 biologics plant from Stelis Biopharma and its first US biologics site, in Baltimore, from Emergent Manufacturing Operations Baltimore, LLC.1415 Syngene is an operationally independent listed subsidiary of Biocon Limited, which holds a majority stake; Kiran Mazumdar-Shaw is its Executive Chairperson.1617
Syngene International key points
Results
- In the quarter to Sep 2026, revenue from operations was ₹833 crore, up 13% from ₹736 crore in the quarter to Jun 2026 and down from ₹911 crore a year earlier.1819
- Operating EBITDA (earnings before interest, tax, depreciation and amortisation, leaving out other income) was ₹147 crore in the quarter to Sep 2026, a margin of 18%, against 12% in the quarter to Jun 2026 and 22% a year earlier.1820
- Profit after tax in the quarter to Sep 2026 was ₹32 crore, after a loss of ₹9 crore in the quarter to Jun 2026, against ₹67 crore a year earlier.2122
- In the year to Mar 2026, consolidated revenue from operations rose 2.6% to ₹37,387 million and EBITDA including other income fell 11.2% to ₹9,892 million; profit after tax was ₹3,167 million, or ₹3,799 million before one-off items, which the company reports separately.2324
Where revenue comes from
Plants and capacity
- In India, Syngene has 5 plants in Bengaluru, 2 in Mangaluru and 2 in Hyderabad; with its US site, its facilities cover over 3 million sq. ft.2728
- Unit 3, the Bengaluru biologics plant, became operational in the year to Mar 2026 for drug substance (the active ingredient) and drug product (the finished medicine), and secured a manufacturing test licence (permission to make test batches) for sterile injectables.29
- The Bayview biologics plant in the USA adds single-use bioreactors (disposable vessels in which cells grow to make biologic drugs) of 2 kL and 4 kL (kilolitres).30
Customers and partners
- Syngene works with about 400 customers, including 16 of the top 20 pharma companies; those it names include BMS, GSK, Zoetis and Merck KGaA.2831
- 2 customers together accounted for ₹13,926 million of consolidated revenue from operations in the year to Mar 2026, more than 10% of the total, against ₹14,987 million a year earlier.32
- Syngene's collaboration with Bristol Myers Squibb, which began in 1998, was extended in January 2026 through 2035 and widened across the drug development lifecycle.3334
- The company said lower Zoetis revenues and forex hedge losses (losses on contracts fixing exchange rates in advance) mainly explained the year-on-year fall in the quarter to Sep 2026; without the hedge loss, operating EBITDA margin would be in the mid-20s.35
Expansion and capital spending
- In its exchange filing of 27 Oct 2026, the company said it had signed its first Bayview manufacturing agreement, with a large pharmaceutical customer, and expects drug substance manufacturing there to begin in the year to Mar 2028.36
- The company stated in its annual report for the year to Mar 2026 that Bayview, once fully integrated, is expected to take its global single-use bioreactor capacity to 50,000 litres.30
- As of its annual report for the year to Mar 2026, Syngene had begun a dedicated bioconjugation facility at Unit 3 for antibody-drug conjugates (antibodies joined to a drug payload) and a dedicated facility to make cytotoxic (cell-killing) drug substances.3037
What the company expects
- In its exchange filing of 29 Jul 2026, the company said it expects a single-digit fall in revenue in rupee terms for the year to Mar 2027, with a weaker first half and a better second half, and EBITDA margins in the mid-20s.38
- In its exchange filing of 27 Oct 2026, the company said its manpower-related cost optimisation was complete, that initiatives on non-manpower costs would continue and that the benefits would be realised over the coming quarters.28
- The company stated in its annual report for the year to Mar 2026 that its emphasis would shift from creating capacity to improving asset utilisation, productivity and returns on invested capital.39
Recent events
- Chief Financial Officer Deepak Jain decided to leave Syngene for personal reasons; the company said on 27 Oct 2026 that he would stay at least until the quarter to Dec 2026 results close.28
- Siddharth Mittal, formerly Managing Director and CEO of Biocon Limited, became Syngene's Managing Director and CEO on 1 Jul 2026, succeeding Peter Bains.4041
Litigation and regulatory matters
- As of its filing of 29 Mar 2026, the High Court of Karnataka had allowed the company's petition against tax refunds of ₹48,90,84,008 being set off against other years' demands or not issued; a refund of ₹43,15,79,510, including interest, was granted but not yet received.42
- In February 2026, the National Faceless Appeal Centre partly allowed the company's income tax appeals for assessment years (the years in which income is taxed) 2015-16, 2018-19 and 2021-22; the company expects lower contingent liabilities (possible dues not recorded as liabilities) and refunds.43
Last updated
All 43 sources, each with its page
- 1. Annual report, 2 Jul 2026, page 7
- 2. Annual report, 2 Jul 2026, page 21
- 3. Annual report, 2 Jul 2026, page 20
- 4. Annual report, 2 Jul 2026, page 188
- 5. Annual report, 2 Jul 2026, page 22
- 6. Annual report, 2 Jul 2026, page 185
- 7. Investor presentation, 27 Oct 2026, page 18
- 8. Annual report, 2 Jul 2026, page 143
- 9. Investor presentation, 27 Oct 2026, page 15
- 10. Investor presentation, 27 Oct 2026, page 12
- 11. Annual report, 2 Jul 2026, page 195
- 12. Annual report, 2 Jul 2026, page 395
- 13. Annual report, 2 Jul 2026, page 30
- 14. Annual report, 2 Jul 2026, page 192
- 15. Investor presentation, 27 Oct 2026, page 11
- 16. Investor presentation, 27 Oct 2026, page 30
- 17. Exchange filing, 27 Oct 2026, page 2
- 18. Exchange filing, 27 Oct 2026, page 2
- 19. Exchange filing, 27 Oct 2026, page 2
- 20. Investor presentation, 27 Oct 2026, page 27
- 21. Exchange filing, 27 Oct 2026, page 2
- 22. Investor presentation, 27 Oct 2026, page 27
- 23. Annual report, 2 Jul 2026, page 198
- 24. Annual report, 2 Jul 2026, page 17
- 25. Annual report, 2 Jul 2026, page 369
- 26. Investor presentation, 27 Oct 2026, page 15
- 27. Annual report, 2 Jul 2026, page 131
- 28. Exchange filing, 27 Oct 2026, page 4
- 29. Annual report, 2 Jul 2026, page 69
- 30. Annual report, 2 Jul 2026, page 47
- 31. Investor presentation, 27 Oct 2026, page 11
- 32. Annual report, 2 Jul 2026, page 369
- 33. Annual report, 2 Jul 2026, page 42
- 34. Annual report, 2 Jul 2026, page 43
- 35. Exchange filing, 27 Oct 2026, page 3
- 36. Exchange filing, 27 Oct 2026, page 3
- 37. Annual report, 2 Jul 2026, page 191
- 38. Exchange filing, 29 Jul 2026, page 3
- 39. Annual report, 2 Jul 2026, page 18
- 40. Annual report, 2 Jul 2026, page 403
- 41. Annual report, 2 Jul 2026, page 396
- 42. Exchange filing, 29 Mar 2026, page 3
- 43. Exchange filing, 18 Feb 2026, page 3
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore.Syngene International quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −6.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −60.3%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹778 Crup 17.33%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹49 CrQuarter to Jun 2026: −₹2.10 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.3%
Revenue by quarter
Peak revenue ₹960 Cr, quarter to Mar 2026; lowest ₹663 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Sep 2026, ₹49 CrA loss in 1 of the 8 quarters shown
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 877 | 948 | 799 | 830 | 834 | 960 | 663 | 778 |
| Net profit | 123 | 174 | 74 | 66 | 17 | 148 | −2 | 49 |
| Net margin | 14.0% | 18.4% | 9.3% | 8.0% | 2.0% | 15.4% | −0.3% | 6.3% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,424 Crup 1.50%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹305 Crdown 34.85%
- Net margin
- 8.9%
Revenue by year
Peak revenue ₹3,424 Cr, year to Mar 2026; lowest ₹1,201 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,201 | 1,423 | 1,826 | 2,012 | 2,179 | 2,601 | 3,194 | 3,203 | 3,373 | 3,424 |
| Net profit | 287 | 305 | 331 | 412 | 404 | 394 | 473 | 467 | 468 | 305 |
| Net margin | 23.9% | 21.4% | 18.1% | 20.5% | 18.5% | 15.1% | 14.8% | 14.6% | 13.9% | 8.9% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Contract Research and Manufacturing Services, which carries all its revenue.
Valuation
Today, against the company's own history.Syngene International PE ratio and valuation
Price to earnings
At or below today's level on 66% of 2,479 trading days over the last 10 years.
LowestHighest
Its median52.87Industry median31.98
Price to book
At or below today's level on 2% of 1,985 trading days since Oct 2018.
LowestHighest
Its median7.16Industry median1.89
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 98% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.17%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −46.0% | −34.9% | −17.6% | 0.3% |
| 3 years | −12.9% | −13.7% | +0.7% | 0.2% |
| 5 years | −6.2% | −5.7% | −0.8% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Mutual fund holdings
120 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 51 of the 64 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 120 funds holding Syngene International
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 5
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 31
- CutCut. Funds that held fewer shares than at the end of the month before.
- 33
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 49
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 1,33,22,540 | 0.60% | ₹486.7 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 79,50,848 | 1.55% | ₹290.4 Cr |
 SBI Multi Asset Allocation FundSBI Mutual Fund | 70,00,000 | 1.22% | ₹255.7 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 65,81,205 | 0.45% | ₹240.4 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 65,78,033 | 3.50% | ₹240.3 Cr |
| Nippon India Focused FundNippon India Mutual Fund | 59,96,046 | 2.71% | ₹219.0 Cr |
 DSP ELSS Tax Saver FundDSP Mutual Fund | 39,03,263 | 0.92% | ₹142.6 Cr |
| ICICI Prudential ELSS - Tax Saver FundICICI Prudential Mutual Fund | 37,70,138 | 1.02% | ₹137.7 Cr |
| DSP Large & Mid Cap FundDSP Mutual Fund | 35,35,665 | 0.75% | ₹129.2 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 35,01,497 | 1.40% | ₹127.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Syngene International insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Syngene International competitors and peers
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Syngene International in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 IndegeneINDGN | 14,300 | 34.79 | 4.26 | +35.8% | −7.8% | 13.2% | 15.2% | 0.38% |
 Suven Life SciencesSUVEN | 7,465 | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,323 | 29.17 | 5.09 | +15.2% | – | 19.1% | 21.4% | 0.38% |
 Novelix PharmaceuticalsNOVELIX | 203 | 55.86 | – | +179.9% | – | 11.3% | 8.7% | 0.00% |
 BilcareBI | 187 | – | 0.95 | −0.9% | – | – | 5.4% | 0.00% |
 TAKETAKE | 164 | 12.76 | 5.28 | – | −68.2% | 49.8% | −5.6% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 163 | – | 2.26 | +66.1% | – | – | 8.8% | 0.00% |
 GlobalSpace Technologies540654 | 86 | – | 1.51 | +37.2% | – | – | 7.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Syngene International dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.25 a share, in 4 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.25 |
| 27 Jun 2025 | Final | ₹1.25 |
| 28 Jun 2024 | Final | ₹1.25 |
| 30 Jun 2023 | Final | ₹0.50 |
| 30 Jun 2023 | Special | ₹0.75 |
| 30 Jun 2022 | Final | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Syngene International announcements
Oct 2026
27 Oct · Management
27 Oct · Management
27 Oct · Results
17 Oct · Analysts
Syngene International share price by year
Each calendar year to 2025.Syngene International share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 651.00 | −24.2% | 879.25 | 609.45 |
| 2024 | 858.45 | +22.4% | 947.80 | 652.00 |
| 2023 | 701.45 | +19.8% | 843.55 | 550.95 |
| 2022 | 585.55 | −5.5% | 663.60 | 526.65 |
| 2021 | 619.90 | −3.1% | 670.00 | 500.70 |
| 2020 | 639.60 | +99.8% | 639.60 | 222.70 |
| 2019 | 320.15 | +14.3% | 352.05 | 270.15 |
| 2018 | 280.10 | +3.5% | 339.60 | 262.60 |
| 2017 | 270.68 | −3.6% | 303.98 | 218.90 |
| 2016 | 280.93 | +34.9% | 317.13 | 175.18 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 386.00 | 418.85 | 374.25 | 410.85 | 402.47 | 3,29,65,479 | 13.9% |
| 27 Oct 2026 | 362.00 | 372.95 | 358.75 | 366.20 | 363.50 | 8,87,125 | 54.6% |
| 26 Oct 2026 | 365.85 | 371.20 | 358.25 | 359.85 | 360.45 | 10,40,080 | 63.9% |
| 23 Oct 2026 | 370.00 | 373.25 | 361.60 | 366.85 | 366.26 | 4,44,231 | 53.8% |
| 22 Oct 2026 | 372.75 | 378.60 | 366.70 | 372.50 | 372.70 | 4,48,590 | 54.0% |
| 21 Oct 2026 | 394.15 | 405.40 | 374.10 | 376.45 | 383.79 | 5,69,207 | 54.0% |
| 19 Oct 2026 | 382.50 | 402.00 | 382.50 | 397.50 | 393.95 | 17,09,879 | 45.5% |
| 16 Oct 2026 | 385.00 | 390.00 | 382.50 | 386.10 | 385.96 | 3,58,384 | 49.2% |
| 15 Oct 2026 | 390.55 | 397.90 | 382.40 | 384.20 | 388.80 | 8,47,215 | 51.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 11 Jun 2019 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- SYNGENE
- BSE code
- 539268
- ISIN
- INE398R01022
- Industry
- Healthcare Services
- Website
- www.syngeneintl.com
- CIN
- L85110KA1993PLC014937
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- Biocon Park SEZ, Jigani Link Road, Bommasandra IV Phase, Bengaluru 560099, Karnataka
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap